Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Arif A, Awan"'
Autor:
Sharon F. McGee, Mark Clemons, Gregory Pond, Jean-Michel Caudrelier, Michelle Liu, Mashari Jemaan Alzahrani, Terry L. Ng, Arif A. Awan, Sandeep Sehdev, John Hilton, Marie-France Savard, Lesley Fallowfield, Vikaash Kumar, Orit Freedman, Lisa Vandermeer, Brian Hutton, Jean-Marc Bourque
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4531-4545 (2024)
Concerns exist regarding increased toxicities, including endocrine therapy toxicity, with concurrent radiation and endocrine therapy in early breast cancer (EBC). We present a pragmatic, randomized trial comparing concurrent versus sequential endocri
Externí odkaz:
https://doaj.org/article/2fd4e23646ed407ea822b33ad3dcffab
Autor:
Ana-Alicia Beltran-Bless, Mark Clemons, Lisa Vandermeer, Khaled El Emam, Terry L. Ng, Sharon McGee, Arif Ali Awan, Gregory Pond, Julie Renaud, Gwen Barton, Brian Hutton, Marie-France Savard
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1376-1388 (2024)
Patients, families, healthcare providers and funders face multiple comparable treatment options without knowing which provides the best quality of care. As a step towards improving this, the REthinking Clinical Trials (REaCT) pragmatic trials program
Externí odkaz:
https://doaj.org/article/f3613d1f36524433a33a1ce65b55e6df
Autor:
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F. K. Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1278-1290 (2024)
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a
Externí odkaz:
https://doaj.org/article/59ac03d441804b9a97079eb978d6a8a8
Autor:
Susan Dent, Dean Fergusson, Olexiy Aseyev, Carol Stober, Gregory Pond, Arif A. Awan, Sharon F. McGee, Terry L. Ng, Demetrios Simos, Lisa Vandermeer, Deanna Saunders, John F. Hilton, Brian Hutton, Mark Clemons
Publikováno v:
Current Oncology, Vol 28, Iss 6, Pp 5073-5083 (2021)
Purpose: The optimal frequency for cardiac monitoring of left ventricular ejection fraction (LVEF) in patients receiving trastuzumab-based therapy for early breast cancer (EBC) is unknown. We conducted a randomized controlled trial comparing 3- versu
Externí odkaz:
https://doaj.org/article/af20337c49a349a1b33516454764a8cc
Publikováno v:
Cancer Medicine, Vol 8, Iss 16, Pp 6871-6886 (2019)
Abstract Background Optimal frequency of follow‐up scans for patients receiving systemic therapies is poorly defined. Progression‐free survival (PFS) generally follows first‐order kinetics. We used exponential decay nonlinear regression analysi
Externí odkaz:
https://doaj.org/article/78106ecf8a894b4580e0cc00f6d51d47
Autor:
Mashari AlZahrani, Mark Clemons, Lisa Vandermeer, Marta Sienkiewicz, Arif Ali Awan, Brian Hutton, Gregory R. Pond, Terry L. Ng
Publikováno v:
Journal of Bone Oncology, Vol 26, Iss , Pp 100339- (2021)
Background: There remain questions around the optimal use of bone-modifying agents (BMAs) in patients with bone metastases from breast and castration-resistant prostate cancer (CRPC). A physician survey was performed to identify current practices, as
Externí odkaz:
https://doaj.org/article/98d068926b794135b1df31a50383b99a
Autor:
Hamza Bari, Arif Ali Awan
Publikováno v:
McGill Journal of Medicine, Vol 8, Iss 1 (2020)
Severe Acute Respiratory Syndrome (SARS) is a serious respiratory illness reported in parts of Asia and Canada. A novel coronavirus (CoV) has been isolated and identified as the cause of the SARS for which there is currently no effective treatment. G
Externí odkaz:
https://doaj.org/article/ad9e8f62b865431c94a5e2edb4a74375
Autor:
Kathleen Anne Bell, Raymond Kim, Melyssa Aronson, Brittany Gillies, Arif Ali Awan, Kathy Chun, Jennifer Hart, Rachel Healey, Linda Kim, Goran Klaric, Karen Panabaker, Peter J B Sabatini, Bekim Sadikovic, Shamini Selvarajah, Amanda C Smith, Tracy L Stockley, Andrea K Vaags, Andrea Eisen, Aaron Pollett, Harriet Feilotter
Publikováno v:
Journal of medical genetics.
BackgroundGenetic testing for hereditary cancer susceptibility has advanced over time due to the discovery of new risk genes, improved technology and decreased cost. In the province of Ontario, testing eligibility criteria were initially developed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8184f8bbffd7499315a996a0936db0c3
https://pubmed.ncbi.nlm.nih.gov/36564171
https://pubmed.ncbi.nlm.nih.gov/36564171
Autor:
Tzu-Fei, Wang, Anna E, Clarke, Arif A, Awan, Peter, Tanuseputro, Marc, Carrier, Manish M, Sood
Publikováno v:
JAMA Network Open. 5:e2219128
Tamoxifen is commonly used as adjuvant therapy in breast cancer and is proposed to interfere with cytochrome P450 enzyme and P-glycoprotein pathways. Concurrent use with direct oral anticoagulants (DOACs) poses the threat of a potentially dangerous d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af5678274fe762ea58721a682710e301
https://doi.org/10.1001/jamanetworkopen.2022.19128
https://doi.org/10.1001/jamanetworkopen.2022.19128
Autor:
Angel Arnaout, Melanie Spears, Arif Ali Awan, Susan Robertson, Kianoosh Keyhanian, Gregory Russell Pond, John Bartlett, Vanessa Lopez-Ozuna, Syed Mahmood, Lewis H. Bender, Ian B. Walters
Publikováno v:
Journal of Clinical Oncology. 40:605-605
605 Background: The INVINCIBLE study is a randomized, Phase 2 presurgical Window-Of-Opportunity trial for IT INT230-6 (comprising VINblastine (VIN) Cisplatin (VIN)) evaluating clinical and BioLogical Effects in patients with early-stage operable Brea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8a67c6d60a638420d73e897a6a21952
https://doi.org/10.1200/jco.2022.40.16_suppl.605
https://doi.org/10.1200/jco.2022.40.16_suppl.605